Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Intuit Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Intuit Inc. trades at $284.98 (market cap $77.26B). The key difference: Intuit Inc. is far larger — about 9.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Intuit Inc. pays a 1.7% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | INTU | |
|---|---|---|
Market Cap | $8.04B | $77.26B |
Sector | Health | Technology |
52-Week High | $339.75 | $807.39 |
52-Week Low | $241.71 | $255.07 |
Enterprise Value | $7.85B | $75.71B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Intuit (INTU) trades at $289.73, up 5.37% in the last session, with a bullish technical signal and strong support at $284. The company reported robust earnings, beating estimates for Q3 2025, Q4 2025, and Q1 2026, with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026. Profit margins improved to 21.91% net income margin, while valuation ratios like P/E of 17.23 and P/S of 3.78 indicate reasonable pricing. However, recent news highlights a 20% stock drop and securities fraud investigations, adding volatility.
Outlook remains positive due to consistent earnings beats and AI-driven growth, but risks include legal scrutiny and competitive pressures. Analysts maintain a 71.11% buy rating with a $422.88 consensus target, suggesting potential upside if the company navigates current challenges effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
